SecBot SecBot
S-1 ·Filed Mar 3, 2026

MDLN

Medline Inc.
NEUTRAL
Impact 4/10
Horizondays Processed8mo ago SEC0001193125-26-086603
IPO registration
Actionable Insight • Neutral

This secondary offering by selling stockholders is a liquidity event for early investors and private equity sponsors, not a capital raise for the company. Traders should monitor the impact of increased public float on stock volatility and the potential for future secondary offerings. The company's strong financials and market position remain the primary drivers of long-term value.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$44.39
T+0 close · Mar 3, 2026 · via day close
Latest settled
−19.26%
T+60 · $35.84
Vs SPY
−29.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $44.39entry
  2. T+1 · 9mo ago −3.40%α −4.16% · $42.88
  3. T+5 · 8mo ago −3.40%α −2.92% · $42.88
  4. T+20 · 8mo ago +0.25%α +4.65% · $44.50
  5. T+60 · 6mo ago −19.26%α −29.58% · $35.84

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Medline Inc. (MDLN) is conducting a secondary offering where selling stockholders are offering 75 million shares of Class A common stock. The company, a leading provider of medical-surgical products and supply chain solutions, reported $28.4 billion in net sales and $1.2 billion in net income for 2025. The offering proceeds go to the selling stockholders, not the company, and follows Medline's initial public offering in December 2025.

Key Financial Metrics

Rev Growth
+11.3%

Key Facts

  • Selling stockholders are offering 75 million shares of Class A common stock; the company will not receive any proceeds.
  • Medline is the largest provider of med-surg products and supply chain solutions, with $28.4 billion in net sales and $1.2 billion in net income for 2025.
  • The company operates under an UP-C structure, with Class B common stock holding 76.8% of voting power after the offering.
  • The offering includes a potential 11.25 million share over-allotment option for the underwriters.
  • The company has a significant tax receivable agreement, with a potential $12.1 billion liability to pre-IPO owners.

Financial Impact

The offering does not generate proceeds for the company. The company reported $28.4 billion in net sales and $1.2 billion in net income for 2025.

revenuenet income

Risk Factors

  • The UP-C structure gives pre-IPO owners significant control (76.8% voting power), which may conflict with public shareholders' interests.
  • The company has a substantial tax receivable agreement liability of $4.0 billion, which could impact future cash flows.
  • The company's revenue growth has slowed, with 2025 revenue growth of 11.3% compared to a 13% 10-year CAGR.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
S-1 Filing (Primary)0001193125-26-086603
Document: d286688dex11.htm0001193125-26-086603
Document: d286688dexfilingfees.htm0001193125-26-086603
Document: d286688dex51.htm0001193125-26-086603
Document: d286688dex231.htm0001193125-26-086603
Document: 0001193125-26-086603-index-headers.html0001193125-26-086603
Document: 0001193125-26-086603-index.html0001193125-26-086603
Document: 0001193125-26-086603.txt0001193125-26-086603

Track record

30 reports on MDLN

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +17.95% at T+20 after the May 6, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bearish 5/10 Entry $36.40 Now $39.17 −7.61% settles Nov 23
  2. Nov 16, 2026today S-1 Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
  4. Nov 13, 20263d ago 144 Neutral 2/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
  5. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $39.17 −3.78% ▼ −3.78% −2.09% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  7. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $40.35 to $42.16 Now $39.17 −2.92% ▲ +4.49% +5.40% vs SPY
  8. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $34.09 to $40.91 Now $39.17 −14.90% ▼ −20.01% −20.59% vs SPY
  9. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $32.12 to $39.64 Now $39.17 +21.95% ▲ +23.41% +26.12% vs SPY
  10. Oct 21, 202626d ago 8-K Bearish 6/10 Entry $34.88 to $32.00 Now $39.17 −12.30% ▲ +8.26% +8.96% vs SPY
Showing 10 of 30

US Market Status

Market Closed · Opens Wed (11h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026